Immunosuppressant biologic treatment in rheumatology

Warning

Information for general practitioners

The aim of treatment is to suppress disease activity and preserve joint/organ function in the inflammatory arthropathies/SLE and vasculitides for those who have failed or are intolerant of methotrexate. Most are co-prescribed with methotrexate for increased efficacy.

At time of writing these are the Biologic/Small Molecule Targeted JAK inhibitor Drugs accepted for use in NHS Scotland:

  • Adalimumab 
  • Certolizumab Pegol 
  • Etanercept 
  • Golimumab 
  • Infliximab 
  • Abatacept 
  • Rituximab 
  • Tocilizumab 
  • Sarilumab 
  • Secukinumab 
  • Bimekizumab
  • Ixekizumab 
  • Ustekinumab 
  • Guselkumab 
  • Upadacitinib 
  • Baricitinib 
  • Tofacitinib 
  • Filgotinib 
  • Anakinra 
  • Belimumab

Dosage

  • Varies according to individual drug
  • Most are self-administered subcutaneously, but some can be used IV or SC
  • Rituximab and Belimumab are IV
  • Infliximab IV or subcutaneous.
  • JAK inhibitors (jakinibs) are oral

 

Vaccination

  • Pneumococcal and annual flu vaccination is recommended prior to treatment
  • Passive immunization with VZIG is recommended if newly exposed to chicken pox
  • No live vaccines can be given, including Herpes Zoster vaccination

 

Monitoring procedure

  • If the patient is receiving standard DMARDs continue usual monitoring for that drug.
  • If on biologics alone - FBC, ESR and U+E, LFTs monthly for 3 months, then 6 monthly unless advised differently by rheumatology, 
  • Exceptions are Tocilizumab and Sarilumab and also the JAK inhibitors (Upadacitinib, Baracitinib, Tofacitinib, Filgotinib)- also require Lipids at 3 months. 

 

Stop treatment if:

  • Evidence of active infection or during antibiotic therapy (then restart unless the infection was serious/life threatening)
  • Significant open wounds
  • Planned or current Pregnancy, pruritis/rash or symptoms of significant allergy
  • Suspected demyelination
  • Tocilizumab and Sarilumab - stop if new abdominal symptoms (diverticulitis risk)
  • Rituximab/Belimumab - stop if new cognitive/psychiatric/neurological symptoms - exceptionally rarely PML
  • WCC -<3.5 - withhold and discuss with rheumatology
  • Neutrophils <1.5
  • Platelets <140
  • AST or ALT >3 times upper limit normal

 

Duration of treatment and time to response

  • Treatment is continued indefinitely as long as it remains effective and without side effects
  • Biologics vary in their time to response – but they are generally stopped after 3 months if no benefit
  • During this period there are likely to be continued symptoms or signs of disease activity
  • It is reasonable to use IM Depomedrone 80mg or Triamcinolone (Kenalog) 80mg

 

Flares

  • Unfortunately Biologic drugs will not prevent all flares
  • Manage fares with IM Depot steroid as outlined under 'duration of treatment and time to response'
  • If increasing frequency of flares, contact the rheumatologist

 

Contraindications

  • Pregnancy (though early data reassuring - especially for Certolizumab Pegol)
  • Breastfeeding (can breastfeed on Adalimumab and Certolizumab Pegol). Note: B_Live vaccines to infant contraindicated for 5 months in general after mother stops biologic agent (including Rotavirus vaccine)
  • Active infection
  • Open leg ulcers
  • previously infected prosthetic joint (unless completely removed)
  • Septic arthritis in the last year
  • HIV or Hepatitis B carriers (usually)
  • Previous malignancy within last 5 years (usually)
  • NYHA grade 3 heart failure
  • Demyelinating disease

 

Relative contraindications

  • Uncontrolled diabetes
  • Pulmonary fibrosis
  • Bronchiectasis
  • PUVA >1000 Joules
  • NYHA grade 1/2
  • previous TB or positive PPD test

 

Hospital contacts

Secretaries 01387 241776

 

 

Rheumatology Nurse Specialists Helpline 01387 241095 or dg.rheum-adviceline@nhs.scot 

 

 

Department of Rheumatology doctors via Switchboard if urgent or RMS Advice request

 

 

Editorial Information

Last reviewed: 19/03/2026

Next review date: 19/03/2028

Reviewer name(s): Lucy Moran.